Kidney Cancer

Readmission Risk Factors for Radical Nephrectomy Patients Identified

Readmission Risk Factors for Radical Nephrectomy Patients Identified

By

Race, procedure and insurance type, sex, surgeon volume, and hospital size influence the risk of readmission among patients undergoing radical nephrectomy, study finds.

Partial vs Radical Nephrectomy Lowers Elderly Patient Mortality Risk

Partial vs Radical Nephrectomy Lowers Elderly Patient Mortality Risk

By

Study shows that partial nephrectomy for small renal tumors is associated with lower risk of cancer-specific and other-cause mortality in patients aged 75 years and older.

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

By

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Smoking Ups Bladder Cancer Risk, Lowers Prostate Cancer Risk

Smoking Ups Bladder Cancer Risk, Lowers Prostate Cancer Risk

By

Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.

Odds of Prescribing Drugs Up With Doc Receipt of Payments

Odds of Prescribing Drugs Up With Doc Receipt of Payments

Doctors who receive general payment for cancer drug more likely to prescribe drug marketed by company.

Nivolumab plus ipilimumab improves survival in advanced renal cell carcinoma

1. Amongst patients with advanced renal-cell carcinoma and an intermediate or poor prognosis, nivolumab plus ipilimumab was superior to sunitinib alone in improving overall survival. 2. Though not statistically compared, there was a lower incidence of grade three or four adverse events with nivolumab plus ipilimumab, although more patients in the combination therapy arm stopped []

Relative Visceral Fat Indicates Mortality Risk for Women With RCC

Relative Visceral Fat Indicates Mortality Risk for Women With RCC

An evaluation of patients with clear cell renal cell carcinoma revealed greater risk of death for female patients with high relative visceral fat area (rVFA), highlighting the significance of metabolic differences between men and women.

Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors

Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors

Myocarditis with ICIs may be more common than initially thought; responds to higher steroid dosages

Older Age May Up Risk for RCC-Related Death After Surgery

Older Age May Up Risk for RCC-Related Death After Surgery

By

The risk of dying from pT1a renal cell carcinoma after partial or radical nephrectomy increases along with patient age.

Nivolumab Plus Ipilimumab Better for Advanced RCC

Nivolumab Plus Ipilimumab Better for Advanced RCC

By

Among intermediate- and poor-risk patients, the risk for death was 37% lower with nivolumab plus ipilimumab than with sunitinib.

Robotic PN May Offer Better Outcomes Than RFA for T1a RCC

Robotic PN May Offer Better Outcomes Than RFA for T1a RCC

By

Two-year recurrence-free survival was 100% vs 95.2% among robotic surgery and radiofrequency ablation patients, respectively.

Small Renal Masses Initially Grow at Variable Rates

Small Renal Masses Initially Grow at Variable Rates

Not reliable predictor of adverse outcomes in those under active surveillance; less variability over time

First-line Pazopanib May Improve Outcomes in Advanced RCC

First-line Pazopanib May Improve Outcomes in Advanced RCC

By

Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

By

The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

By

In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

By

Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

By

Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.

Urologic Cancer Surgery Readmission Rate Highest for RC

Urologic Cancer Surgery Readmission Rate Highest for RC

By

In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.

Jury Still Out on Whether Immunotherapy Can Cure Metastatic RCC

Jury Still Out on Whether Immunotherapy Can Cure Metastatic RCC

Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.

Robotic Partial Nephrectomy Feasible for Larger Kidney Tumors

Robotic Partial Nephrectomy Feasible for Larger Kidney Tumors

By

No greater risks for upstaging or positive surgical margins were observed among patients who underwent RPN for cT2a tumors over the short term.

Kidney Cancer Progression Linked to Preop Cardiovascular Biomarkers

Kidney Cancer Progression Linked to Preop Cardiovascular Biomarkers

By

Elevated serum levels of BNP and NT-proBNP prior to nephrectomy are associated with an increased likelihood of RCC progression.

Regional variation in CT imaging is associated with nephrectomy risk

1. Regional variation in cumulative risk of an individual having a chest or abdominal CT in the United States was positively correlated with the risk of both total and partial nephrectomy, as well as any renal procedure (including renal ablation). 2. This association may reflect incidental detection and over-diagnosis of renal masses, with an increased []

RCC Treatment Costs Could Negatively Affect Health

RCC Treatment Costs Could Negatively Affect Health

Access to treatment should be considered as important as the research leading to clinical improvements.

Radical Nephrectomy Linked With Worse Kidney Function, Survival

Radical Nephrectomy Linked With Worse Kidney Function, Survival

By

Patients who underwent radical nephrectomy had 2-fold greater decline in eGFR decline and 2-fold greater mortality compared with those who had a partial nephrectomy.

Cabozantinib Improves Survival, Response in Bone-metastatic RCC

Cabozantinib Improves Survival, Response in Bone-metastatic RCC

Patients who received cabozantinib were also less likely to have skeletal-related events (23% vs 29% with everolimus).

3D Printing Surgical Models for Kidney Cancer Care

3D Printing Surgical Models for Kidney Cancer Care

By

Renal & Urology News spoke with Jonathan Silberstein, MD, about creating surgical models using a 3D printer.

SABR for Renal Cell Carcinoma Offers Excellent Outcomes

SABR for Renal Cell Carcinoma Offers Excellent Outcomes

By

Stereotactic ablative radiotherapy is associated with high 2- and 4-year rates of local cancer control and progression-free and cancer-specific survival.

Conversion of Robotic Partial to Radical Nephrectomy Is Uncommon

Conversion of Robotic Partial to Radical Nephrectomy Is Uncommon

By

In a multinational, prospective study, just 5% of cases converted.

Adverse Events Up for Autoimmune Disease Pts on Checkpoint Inhibitors

Adverse Events Up for Autoimmune Disease Pts on Checkpoint Inhibitors

Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.

Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma

Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma

Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.

Sign Up for Free e-newsletters